Literature DB >> 21521703

Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.

Ian M Gould1.   

Abstract

Current concerns about multiresistance and a diminishing antibiotic pipeline are mainly addressed to Gram-negative bacteria. The greatest fear within the Gram-positive arena is vancomycin-resistant Staphylococcus aureus. Its epidemiology and clinical presentation give cause for concern, but so far its impact has been strictly limited. While this may change, the loss of glycopeptides as a treatment option may not, in fact, be all bad news.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21521703     DOI： 10.1093/jac/dkr073

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  10 in total

1.  Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.

Authors:  Rodrigo E Mendes; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

2.  Impact of Staphylococcus aureus accessory gene regulator (agr) system on linezolid efficacy by profiling pharmacodynamics and RNAIII expression.

Authors:  Rachel L Soon; Justin R Lenhard; Irene Reilly; Tanya Brown; Alan Forrest; Brian T Tsuji
Journal:  J Antibiot (Tokyo)       Date:  2016-06-08       Impact factor: 2.649

3.  VanA and VanB Positive Vancomycin-resistant Staphylococcus aureus Among Clinical Isolates in Shiraz, South of Iran.

Authors:  Sareh Saadat; Kavous Solhjoo; Mohammad-Javad Norooz-Nejad; Akbar Kazemi
Journal:  Oman Med J       Date:  2014-09

4.  Regional resistance surveillance program results for 12 Asia-Pacific nations (2011).

Authors:  Rodrigo E Mendes; Myrna Mendoza; Kirnpal K Banga Singh; Mariana Castanheira; Jan M Bell; John D Turnidge; Stephen S F Lin; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

5.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

6.  Antibacterial activities of Groebke-Blackburn-Bienaymé-derived imidazo[1,2-a]pyridin-3-amines.

Authors:  Nikunj M Shukla; Deepak B Salunke; Euna Yoo; Cole A Mutz; Rajalakshmi Balakrishna; Sunil A David
Journal:  Bioorg Med Chem       Date:  2012-08-08       Impact factor: 3.641

7.  Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli.

Authors:  Rodrigo E Mendes; M R K Alley; Helio S Sader; Douglas J Biedenbach; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

8.  Increased drug resistance of meticillin-resistant Staphylococcus aureus biofilms formed on a mouse dermal chip model.

Authors:  Shiro Jimi; Motoyasu Miyazaki; Tohru Takata; Hiroyuki Ohjimi; Sadanori Akita; Shuuji Hara
Journal:  J Med Microbiol       Date:  2017-04       Impact factor: 2.472

9.  Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves.

Authors:  Som S Chatterjee; Michael Otto
Journal:  Clin Epidemiol       Date:  2013-07-04       Impact factor: 4.790

10.  Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011).

Authors:  Ronald N Jones; Manuel Guzman-Blanco; Ana C Gales; Belisario Gallegos; Aura Lucia Leal Castro; Marines Dalla Valle Martino; Silvio Vega; Jeannete Zurita; Mario Cepparulo; Mariana Castanheira
Journal:  Braz J Infect Dis       Date:  2013-10-10       Impact factor: 3.257
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.